CAMBRIDGE, Mass. Sage Therapeutics (SAGE, Financials) announced a massive shakeup under its reorganization plan Thursday, led by a 33% reduction in its workforce, in supporting the launch of ZURZUVAE, its treatment for postpartum depression. Additionally, the reshuffling will enable the company to focus on advancing pipeline development before a key clinical readout for dalzanemdor, a drug candidate for Huntington's disease, that is slated to be released later this year.
The move, likely to offset over 165 employees, including 55% of its R&D staff, entails strengthening the company's balance sheet while extending its cash runway. The restructuring is set to be completed by Q4 2024.
Several executives will depart as part of the changes, including Anne Marie Cook, Kimi Iguchi, Matt Lasmanis, Heinrich Schlieker, and Amy Schacterle. Chris Benecchi will be looking to take up the reins as Chief Operating Officer, overseeing several departments, while Greg Shiferman and Vanessa Procter will assume expanded leadership roles.
Sage's reorganization positions the company for the company's long-term expansion while managing costs and improving efficiency during ZURZUVAE's market introduction phase.
This article first appeared on GuruFocus.免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。